Drug Chatter -- Tracking biopharma stock chatter

DrugPatentWatch - Biopharmaceutical Business Intelligence

Profile for Aldeyra Therapeutics, Inc. (ALDX)

« Back to company index

ALDX Chatter Timeline

Stock Ticker for ALDX

Most Active Tweeters for ALDX

UserTweets
@fezziwig2008 12
@AmericanBanking 3
@ZolmaxNews 1
@littlecreepy 1
@macondailynews 1

Recent Tweets for ALDX

ThisLincolnian @ThisLincolnian
-$0.51 EPS Expected for Aldeyra Therapeutics, Inc $ALDX This Quarter https://t.co/GULtu4p9hf
July 15th 2019, 12:07pm
fezziwig2008 @fezziwig2008
$ALDX filter needed on #juul https://t.co/FUs14AT3gG
July 15th 2019, 11:07am
fezziwig2008 @fezziwig2008
$ALDX reproxalap traps e-cigarette emitted aldehydes- “Frankly, we don’t know [the impact of chronic vaping] today… https://t.co/YnGiLEOHP3
July 15th 2019, 9:07am
ConsumerFeed @ConsumerFeed
Analyzing SUMMIT THERAPEU/S $SMMT and Aldeyra Therapeutics $ALDX https://t.co/Sus4Qd1Wf6
July 15th 2019, 3:07am
macondailynews @macondailynews
Aldeyra Therapeutics $ALDX Rating Lowered to Sell at Zacks Investment Research https://t.co/P7ZFgexXMf
July 14th 2019, 7:07am
ZolmaxNews @ZolmaxNews
Aldeyra Therapeutics $ALDX Rating Lowered to Sell at Zacks Investment Research https://t.co/LXmhijj2fF
July 14th 2019, 7:07am
TheMarketsDaily @TheMarketsDaily
Aldeyra Therapeutics $ALDX Rating Lowered to Sell at Zacks Investment Research https://t.co/ncWt0xAQkQ
July 14th 2019, 7:07am
bbnsnews @bbnsnews
Aldeyra Therapeutics $ALDX Downgraded by Zacks Investment Research https://t.co/9FLlYt3r1y
July 13th 2019, 6:07am
AmericanBanking @AmericanBanking
Aldeyra Therapeutics, Inc $ALDX Receives Consensus Rating of “Buy” from Analysts https://t.co/EoOe4WZxJW #stocks
July 13th 2019, 2:07am
fezziwig2008 @fezziwig2008
@renaud_glen Reached significance in Moderate Uveitis $ALDX
July 12th 2019, 3:07pm
fezziwig2008 @fezziwig2008
@renaud_glen Furthermore -I’m adding $ALDX on ADX-1612 activity in #OvarianCancer w/PARP inhibitors and Platinum Rx… https://t.co/mnnGoHCewe
July 12th 2019, 10:07am
WKRBNews @WKRBNews
Aldeyra Therapeutics $ALDX Downgraded to Sell at Zacks Investment Research https://t.co/pZ4f0eT8BE #markets
July 11th 2019, 8:07pm
dakotafinancial @dakotafinancial
Aldeyra Therapeutics $ALDX Downgraded to Sell at Zacks Investment Research https://t.co/Kwvywoeujo
July 11th 2019, 8:07pm
TickerReport @TickerReport
Critical Analysis: SUMMIT THERAPEU/S $SMMT vs. Aldeyra Therapeutics $ALDX https://t.co/nsmbHk8kKG
July 11th 2019, 1:07am
AmericanBanking @AmericanBanking
Zacks: Analysts Anticipate Aldeyra Therapeutics, Inc $ALDX Will Post Earnings of -$0.51 Per Share https://t.co/zfbbIDbAND #stocks
July 10th 2019, 6:07pm
littlecreepy @littlecreepy
$KOD is bailing me out of my $ALDX trash position
July 10th 2019, 1:07pm
fezziwig2008 @fezziwig2008
Ganetespib’s - ADX 1612 and 1615 (oral form) which $ALDX bought from $MDGL - utility is Platinum specific- therefor… https://t.co/4Je8rItzS6
July 10th 2019, 10:07am
fezziwig2008 @fezziwig2008
RT @fezziwig2008: Mesothelioma & Ovarian Cancer are susceptible to Platinum therapy-their cancer cells escape via DNA Repair-where $ALDX ow…
July 10th 2019, 9:07am
AmericanBanking @AmericanBanking
SUMMIT THERAPEU/S $SMMT versus Aldeyra Therapeutics $ALDX Head to Head Contrast https://t.co/wEJgyewb4H #stocks
July 8th 2019, 10:07pm
fezziwig2008 @fezziwig2008
$ALDX Clinical Programs for Systemic Immune-Mediated Dis. Expected to Begin in 2019. A P2 clinical trial of ADX-161… https://t.co/urNdV7yF1G
July 8th 2019, 10:07am
fezziwig2008 @fezziwig2008
RT @fezziwig2008: 96% Disease Control rate from $ALDX in Malignant Mesothelioma vs 76% rate with $MRK Keytruda. Small study encourages larg…
July 8th 2019, 7:07am
HeadlinesFin @HeadlinesFin
683 Capital Management LLC Stake in Aldeyra Therapeutics INC $ALDX Has Boosted by $3.66 Million https://t.co/NHE5HUIRVC
July 6th 2019, 3:07pm
StockflareUS @StockflareUS
$ALDX: The recommendation for Aldeyra Therapeutics Inc has been downgraded to Buy. (https://t.co/pJK2aWlP8g)
July 5th 2019, 5:07am
fezziwig2008 @fezziwig2008
RT @fezziwig2008: Why $ALDX Reproxalap dual indication will sell : “Perhaps most important, Rx options for 1 condition can actually worsen…
July 3rd 2019, 10:07am
fezziwig2008 @fezziwig2008
RT @fezziwig2008: $ALDX Clinical Programs for Systemic Immune-Mediated Dis. Expected to Begin in 2019. A P2 clinical trial of ADX-1612 in p…
July 3rd 2019, 6:07am
fezziwig2008 @fezziwig2008
$ALDX Clinical Programs for Systemic Immune-Mediated Dis. Expected to Begin in 2019. A P2 clinical trial of ADX-161… https://t.co/LUACf9WuDG
July 2nd 2019, 1:07pm
fezziwig2008 @fezziwig2008
96% Disease Control rate from $ALDX in Malignant Mesothelioma vs 76% rate with $MRK Keytruda. Small study encourage… https://t.co/k6xTEJTq97
July 2nd 2019, 1:07pm
fezziwig2008 @fezziwig2008
RT @fezziwig2008: $ALDX For Mesothelioma-“MESO-2 Data highly encouraging. Adding ADX-1612 to pemetrexed & cisplatin or carboplatin>ORR of 6…
July 1st 2019, 2:07pm
fezziwig2008 @fezziwig2008
$ALDX For Mesothelioma-“MESO-2 Data highly encouraging. Adding ADX-1612 to pemetrexed & cisplatin or carboplatin>OR… https://t.co/BET0RnwuNl
July 1st 2019, 8:07am
Tickeron @Tickeron
A.I.dvisor made a bearish call on $ALDX, netting in a 12.79% gain over 2 weeks https://t.co/DZXAXz9QwC https://t.co/FCfXmaHpyt
June 29th 2019, 9:06pm
ChartMill @ChartMill
$ALDX: Comparing the growth rate of the last 5 years to the rate of the upcoming 2 years, we see that the growt ...… https://t.co/ilQxzoM1Cx
June 29th 2019, 7:06am
stocknewstimes @stocknewstimes
Aldeyra Therapeutics $ALDX Given a $33.00 Price Target by Cantor Fitzgerald Analysts https://t.co/K25wjCaCqP
June 29th 2019, 2:06am
SleekMoneycom @SleekMoneycom
Aldeyra Therapeutics $ALDX Given a $33.00 Price Target by Cantor Fitzgerald Analysts https://t.co/5tUMWBLWRq #investing
June 29th 2019, 2:06am
TheMarketsDaily @TheMarketsDaily
Aldeyra Therapeutics $ALDX Given a $33.00 Price Target by Cantor Fitzgerald Analysts https://t.co/oWnIX4rWFT
June 29th 2019, 2:06am
storminvestor @storminvestor
Aldeyra Therapeutics $ALDX Given a $33.00 Price Target by Cantor Fitzgerald Analysts https://t.co/I5DDlI8VWE #markets
June 29th 2019, 2:06am
TranscriptDaily @TranscriptDaily
Aldeyra Therapeutics $ALDX Given a $33.00 Price Target by Cantor Fitzgerald Analysts https://t.co/L8CVEchYNF
June 29th 2019, 2:06am
dakotafinancial @dakotafinancial
Aldeyra Therapeutics $ALDX Shares Gap Down to $6.21 https://t.co/IrNSNV45qg
June 29th 2019, 12:06am
fezziwig2008 @fezziwig2008
Why $ALDX Reproxalap dual indication will sell : “Perhaps most important, Rx options for 1 condition can actually w… https://t.co/cBKZej5klO
June 28th 2019, 11:06am
fezziwig2008 @fezziwig2008
Noninfectious Anterior Uveitis is to #DryEyeDisease what Atrial Flutter is to #MyocardialInfarction. $ALDX
June 28th 2019, 11:06am
fezziwig2008 @fezziwig2008
$ALDX is being punished for significantly suppressing NAU better in Moderate cases than in mild - think which has m… https://t.co/VBL2lBZf76
June 28th 2019, 10:06am
brendan_49 @brendan_49
@XBIcallTSLAput Seriously. $SPRO dropped more today with out apparent reason than $ALDX did on ph3 uveitis fail!!! Biotech ????
June 27th 2019, 4:06pm
fezziwig2008 @fezziwig2008
RT @fezziwig2008: $ALDX has to settle for dual indications for Reproxalap -stellar p values in Dry eye P2b and already-met primary endpoint…
June 27th 2019, 1:06pm
fezziwig2008 @fezziwig2008
$ALDX has to settle for dual indications for Reproxalap -stellar p values in Dry eye P2b and already-met primary en… https://t.co/VWF5sTdB4a
June 27th 2019, 11:06am
dailymailtimes @dailymailtimes
Aldeyra Therapeutics $ALDX Shares Gap Down to $6.21 https://t.co/fWmCeJtpen #investing
June 26th 2019, 11:06pm
midetimes @midetimes
Aldeyra Therapeutics $ALDX Shares Gap Down to $6.21 https://t.co/Rmd3uon1WQ #stocks
June 26th 2019, 11:06pm
dailypoliticaln @dailypoliticaln
Aldeyra Therapeutics $ALDX Shares Gap Down to $6.21 https://t.co/WZMAx0o1VJ
June 26th 2019, 11:06pm
ZolmaxNews @ZolmaxNews
Aldeyra Therapeutics $ALDX Shares Gap Down to $6.21 https://t.co/cbV24DHt2Q
June 26th 2019, 11:06pm
WatchlistN @WatchlistN
Aldeyra Therapeutics $ALDX Shares Gap Down to $6.21 https://t.co/dFJsBtXgwg
June 26th 2019, 11:06pm
Tickeron @Tickeron
$ALDX Aldeyra Therapeutics (ALDX, $6.21) drops -34% over the last 3 months. Expect a Downtrend reversal https://t.co/sTBE41qq38
June 26th 2019, 6:06pm
ConsumerFeed @ConsumerFeed
Aldeyra Therapeutics $ALDX Given a $33.00 Price Target at Cantor Fitzgerald https://t.co/d33cnEFADE
June 26th 2019, 5:06pm

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2019. All rights reserved.